INKLUDE: FURTHER INFORMATION
WHAT IS INTERSTITIAL LUNG DISEASE?
Interstitial lung disease is a term for a large group of diseases that lead to progressive scarring of the lung, leading to damage and difficulty breathing. There are many different factors that can stimulate the scarring, including bacteria, dusts, pollution, as well underlying genetic susceptibility.
WHY ARE YOU FOCUSSING ON BRAZIL?
As in many developing nations the burdens of interstitial lung disease are high in Brazil. Clinical expertise in recognising the condition is rare and access to that care is sparse. The factors that can lead to scarring are widespread at industrial and artisan level, impacting on livelihoods. Improving awareness and clinical support can reduce the risks to vulnerable groups and enhance appropriate care pathways.
WHAT WILL THE NETWORK DO?
INKLUDE has been awarded a grant by the Global Challenges Research Fund, a UK Research and Innovation initiative to address UN sustainable goals and global challenges in developing nations. We will invite stakeholders to a network meeting where strategies will be co-developed to improve interstitial lung disease management in Brazil. Successful strategies will tailored and adopted to other developing nations.
WHO ARE THE STAKEHOLDERS?
Stakeholders include anyone who is directly involved or interested in improving interstitial lung disease management in developing nations. This includes representatives of the people who are diagnosed, the doctors in rural clinics, the expert clinicians in larger cities, the researchers and entrepreneurs who can build and test new strategies, organisations and governments who can improve public awareness, and representatives of the industries and trades that heighten risks.
WHY ARE YOU INTERESTED IN COVID-19?
The SARS-CoV-2 global pandemic has highlighted the vulnerabilities that exist in our communities and health services, which must be addressed in order to protect our wellbeing and the economy. COVID-19 provides a spotlight on the main barriers people face in accessing urgent and fair healthcare across a diverse developing nation. In addition, early evidence shows persisting health problems after initial recovery, including interstitial lung disease. Insights gained about service use could help minimise severe outcomes.